News

Single-cell proteomics is now established, and we are pleased to offer our expertise for projects where only a few cells can be collected or where the biological state of individual cells must be examined.

We have set up two robotic platforms, AssayMap BRAVO and Andrew+, on which we will perform increasingly automated sample preparation. Protocols for phosphopeptide enrichment and single-cell proteomics are already in place.

In February 2023, we replaced the first-generation QExactive Orbitrap system with a timsTOF HT. In October 2024, we replaced the QExactive HF with an Orbitrap Astral. Additionally, the timsTOF Pro, which was installed in 2020, was upgraded to a timsTOF HT in February 2025.

In collaboration with NCCR RNA & Disease, we have developed a pipeline to analyze the immunopeptidome of the major histocompatibility complex I (MHC-I).  MHC-I plays a central role in immune regulation by presenting short peptides of intracellularly degraded proteins on the cell surface to immune-competent CD8+ T cells. Nonsense-mediated mRNA decay (NMD) is an evolutionarily conserved mechanism that destroys aberrant mRNA. Somatic mutations accumulate in cancer cells, and NMD removes nonfunctional mRNA from them. Consequently, a significant proportion of potential neoantigens are not produced or presented on the surface of cancer cells. We investigated how NMD could be manipulated to reverse this situation and trigger an immune response against cancer cells.

(Last updated on June 19, 2026)